A court has overturned a ruling by a federal judge repeatedly in the spotlight for his decisions, finding in the latest case that a fraud claim against a property purchaser in a dispute with bankruptcy trustees was a notion developed, pursued and upheld by the judge himself.
Although the settlement sum has not been disclosed, court documents in the Opal Tower class action reveal the litigation funder backing the case will seek $13.2 million in commission when the parties appear before the court later this year.
T-shirts and face masks sold on Redbubble violate Hells Angels’ trademarks, a judge has found, banning the online marketplace from further sales of infringing products and awarding damages to the motorcycle group.
His property development empire was saved from liquidation, but Daniel Grollo is still being hounded by creditors, with Bank of Queensland suing the Grocon CEO for the outstanding balance on a $12 million home loan.
A judge has put a climate change class action on behalf of Torres Strait Islanders on a tight timetable and committed herself to handing down judgment soon after trial, saying the case was one of “considerable urgency”.
ANZ is optimistic its proposed $4.9 billion acquisition of insurer Suncorp’s banking unit will be cleared by the competition regulator, and is counting on the public benefits of the merger to win approval.
The finance arm of luxury car maker BMW has been given the greenlight to repossess a red 2019 Ferrari 488 Pista Coupe purchased by alleged fraudster Bill Papas’ defunct Forum Group.
Booktopia has resolved a case by the consumer regulator alleging the online book retailer’s policy that required customers to request a refund within two business days of purchase was misleading.
A long-serving Virgin Australia flight attendant who was found sleeping on the job was unfairly sacked given the length of her employment with the airline, the Fair Work Commission has found.
German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.